Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

"The story provides the cost of the CT scan as well as angiography. However, the story should have discussed insurance coverage for the scans. The story describes the percentage of patients with blockages that were identified with either the CT scan or the angiogram. The story should have also described the probability of having blockages with a positive scan (positive predictive value). This is the more important piece of information to a consumer. Also not described in the story is whether the CT scans had any impact at all on downstream outcomes, such as heart attacks, deaths, or procedures. The story correctly describes radiation exposure as one of the harms of the heart CT. The story could have described other harms, such as theimplications offalse positive or false negativetest results. The story adequately describes the design of the current study, including a criticism from one expert that the study ""cherry-picked"" patients to include in the study in order to maximize the findings. The story does not exaggerate the seriousness or prevalence of heart disease. However, the story could have been more clear about who the CT scans are intended for. The study in question was in those with suspected heart disease, not the assymptomatic or ""worried well"". The use of CT scans in the larger asymptomatic population is controversial. The story quotes multiple independent experts who provide valuable commentary on the implications of the new findings. The story mentions angiography as the alternative to the heart CT. The story clearly states that the CT scans are relatively new and available in many hospitals, however it is not clear how many hospitals have purchased these machines. The story adequately describes the novelty of the scans. Because the story quotes multiple experts, the reader can assume that the story did not rely on a press release as the sole source of information."
'Super X-rays' show promise for finding heart disease but produce high radiation dose

Alex Azar, speaking in Uganda, told reporters that he and others are "very concerned" and urged Tanzania's government to share laboratory results regarding the case. The Ebola outbreak in neighboring Congo has become the second-deadliest in history, with confirmed cases now exceeding 3,000. Azar said efforts were underway to secure Tanzania's compliance with international health regulations and obligations to the World Health Organization "to protect Tanzanians as well as all people in the region." Tanzania's government said Saturday there is no confirmed case of Ebola in the East African nation. No confirmed Ebola case has ever been recorded there. WHO in a statement last week noted a rumor regarding a death in Tanzania from an unknown illness and said it was sending a technical team to investigate "as a matter of urgency." According to an internal WHO document seen by The Associated Press, the patient, a 34-year-old woman, died on Sept. 8 and was buried that day. It was not clear where she died. The document says the victim most recently was a student in central Uganda, where she visited health facilities on a research mission, before returning to Tanzania on Aug. 22. No case of Ebola has been reported in Uganda's central region. "This mysterious disease has to be investigated and samples have to be tested. We couldn't rule out any of the viral hemorrhagic fevers and the investigation will continue," Dr. Yonas Woldemariam, the WHO representative in Uganda, said Monday. The Ebola outbreak in eastern Congo, which was declared over a year ago, has killed nearly 2,000 people. Health workers have been challenged by community mistrust and insecurity caused by years of rebel attacks. Cases of Ebola patients crossing borders during this outbreak have been rare. In June, a family of Congolese with sick family members crossed into Uganda via a bush path. Two died of Ebola inside Uganda. And in August, a Congolese girl tested positive for Ebola and later died in Uganda after traveling from Congo. ___ Follow Africa news at https://twitter.com/AP_Africa
US urges transparency in Ebola-like death in Tanzania.

Oly Ilunga, who opposed using the vaccine developed by U.S. pharmaceutical giant Johnson & Johnson, resigned as minister on Monday after being bumped off the Ebola response team. The World Health Organization recommended the two-dose shot to complement a vaccine by U.S. drugmaker Merck, which has proved highly protective but is in relatively short supply. Proponents, including medical charity Medecins Sans Frontieres (Doctors Without Borders) and the Wellcome Trust, said the new vaccine could be deployed to areas not yet affected by Ebola to create a firewall against the virus, which the WHO declared an international health emergency last week. But Ilunga said the J&J vaccine had not been proven effective and could confuse people in eastern Democratic Republic of Congo, where wild rumours are hampering the response. "Congolese have the right to have the gold standard, the best vaccine," he told Reuters on Thursday, in his first public comments since resigning. "They don't need to be the subject of experimentation." "You can't have a group of promoters, producers of the vaccine (and) university researchers wanting to introduce the vaccine without contacting the health authorities," he said, without elaborating further. Paul Stoffels, J&J's chief scientific officer, denied there were any efforts to secretly introduce the vaccine and said the company had been in full communication with Congolese authorities. But scepticism about new medicines can resonate strongly on a continent where some pharmaceutical trials have faced accusations in the past of failing to obtain informed consent and providing subpar care to participants. For example, some U.S. government-funded trials of HIV drugs in the 1990s were accused of double standards for giving placebos to women in Africa when effective therapies existed, a practice that is not generally allowed in the United States and other Western nations on ethical grounds. Researchers defended the use of placebos as scientifically necessary. Jean-Jacques Muyembe, an epidemiologist and Ebola expert named to lead Congo's response team, dismissed Ilunga's concerns and said authorities would revisit whether to deploy a second vaccine. However, he downplayed the importance of the decision. "I don't think that a vaccine is what's holding back the response," he told Reuters, noting that previous Ebola outbreaks had been contained quickly without a vaccine. "We could use or not use. It won't change the evolution of the epidemic," he said. The nearly year-long outbreak has infected more than 2,500 people and killed more than 1,700, numbers topped only by a 2014-16 outbreak in West Africa that killed more than 11,300. This month, a case was detected in Goma, a city of 2 million on the border with Rwanda, heightening fears about the spread of the haemorrhagic fever. Efforts to contain it have been undermined by mistrust of health workers and violence by armed militias. Treatment centres have been attacked. Local campaigners say people are scared and confused about the various medicines being used. In addition to the vaccine, four experimental treatments are being given to Ebola patients. All are still unlicensed, which means they can only be used in clinical trials overseen by Congo's health ministry. "We should not introduce a second vaccine when we don't yet have scientifically-proven conclusions from the one currently being tested," said Matina Mwanack, the administrator of an advocacy group in the eastern Congo city of Butembo called Families United Against Ebola. "(We) have suffered a lot from the lack of needed information about the vaccines and treatments being tested." Omar Kavota, who heads a group of religious and political leaders in eastern Congo, said "introducing a second vaccine would amplify rumours", including over why some patients got one while others received the second. Muyembe said communicators had been appointed to make the process more transparent. Proponents of a second vaccine argue it can only be tested in a live outbreak, since it would be unethical to deliberately infect trial volunteers. They propose deploying it where the disease has not yet spread, while the Merck vaccine continues to be used to protect contacts of suspected cases. "Both vaccines should work hand in hand," said Peter Piot, director of the London School of Hygiene and Tropical Medicine and one of the scientists who first discovered the Ebola virus. Since the West African outbreak, J&J has tested its vaccine on more than 6,000 volunteers in a dozen trials, confirming its safety and ability to generate an immune response. It requires two injections 56 days apart - another obstacle cited by Ilunga - in an area where fighting causes frequent displacement, but should last longer. "The goal is to give a long-term safe profile for people who may never be exposed to Ebola," said J&J's Stoffels, adding that 1.5 million doses were available. Josie Golding, head of epidemics at the Wellcome Trust, said "we could run out of Merck vaccines" if the outbreak extends into a second year. Health authorities have already begun using smaller doses to ration supplies. Congo's health ministry disputes there is a shortage of the Merck vaccine. The company said it expects to have about 900,000 doses available over the next six to 18 months, in addition to the 195,000 doses it has already donated. The ministry has also considered potential vaccines developed by China's CanSino Biologics and the Russian research institutes Rospotrebnadzor and Gamaleya, but those discussions are less advanced. (GRAPHIC: In Africa, a virus spreads: tmsnrt.rs/2ReWwZU)
Deployment of second Ebola vaccine would not be quick fix, experts warn.